miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway

PURPOSE: Ductal carcinoma in situ (DCIS) is well-known precursor of invasive ductal carcinoma (IDC). Parts of patients show recurrence as DCIS or IDC after local treatment, but there are no established markers predicting relapse. We analyzed changes in miRNA and oncogene expression during DCIS progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jieun, Kim, Hee Eun, Song, Young-Seok, Cho, Eun Yoon, Lee, Ahwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548759/
https://www.ncbi.nlm.nih.gov/pubmed/30989460
http://dx.doi.org/10.1007/s10549-019-05192-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548759/
https://www.ncbi.nlm.nih.gov/pubmed/30989460
http://dx.doi.org/10.1007/s10549-019-05192-1

Ejemplares similares